Search results for "microsatellite instability"

showing 10 items of 69 documents

Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status

2019

The CD274 (programmed cell death ligand-1, PD-L1)/PDCD1 (programmed cell death-1, PD-1) pathway is crucial suppressor of the cytotoxic immune response. Antibodies targeting CD274 or PDCD1 have been revealed to be effective in several malignancies. In colorectal cancer, the response to CD274/PDCD1 blockage is associated with microsatellite instability. However, the value of CD274/PDCD1 for predicting response to treatment or survival benefit is still unclear. The aims of the study were (1) to clarify differences in immune microenvironment and expression of checkpoint proteins (CD274/PDCD1) in DNA mismatch repair-proficient, mismatch repair-deficient, and hereditary Lynch syndrome-associated …

Male0301 basic medicineOncologymedicine.medical_specialtyPathologyColorectal cancerProgrammed Cell Death 1 ReceptorCellDNA Mismatch RepairB7-H1 AntigenPathology and Forensic Medicine03 medical and health sciencesLymphocytes Tumor-Infiltrating0302 clinical medicineImmune systemInternal medicinePD-L1Biomarkers TumorTumor MicroenvironmentmedicineHumansCytotoxic T cellAgedbiologybusiness.industryMicrosatellite instabilityMiddle Agedmedicine.diseaseColorectal Neoplasms Hereditary Nonpolyposis030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisbiology.proteinFemaleDNA mismatch repairAntibodyColorectal Neoplasmsbusiness
researchProduct

Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment

2016

// Marta Jessica Llorca-Cardenosa 1, * , Tania Fleitas 1, * , Maider Ibarrola-Villava 1 , Maria Pena-Chilet 1 , Cristina Mongort 2 , Carolina Martinez-Ciarpaglini 2 , Lara Navarro 2 , Valentina Gambardella 1 , Josefa Castillo 1 , Susana Rosello 1 , Samuel Navarro 2 , Gloria Ribas 1 , Andres Cervantes 1 1 Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain 2 Department of Pathology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain * These authors contributed equally to this work Correspondence to: Gloria Ribas, email: gribas@incliva.es Andres Cervantes, email: andres.cervantes@uv.es Keywords: RUNX3, ARID1A, gastric ca…

Male0301 basic medicineRUNX3immune microenvironmentBiologyEpigenesis Genetic03 medical and health sciences0302 clinical medicineStomach NeoplasmsCDKN2ABiomarkers TumorTumor MicroenvironmentmedicineHumansEpigeneticsPromoter Regions GeneticAgedAged 80 and overTumor microenvironmentgastric cancerMicrosatellite instabilityCancerMethylationDNA MethylationMiddle AgedPrognosismedicine.diseaseARID1Adigestive system diseasesSurvival RateCore Binding Factor Alpha 3 Subunit030104 developmental biologyOncologyTumor progressionCase-Control Studies030220 oncology & carcinogenesisDNA methylationImmunologyCancer researchCpG IslandsFemaleMicrosatellite InstabilityFollow-Up StudiesResearch Papergene methylationOncotarget
researchProduct

The Different Immune Profiles of Normal Colonic Mucosa in Cancer-Free Lynch Syndrome Carriers and Lynch Syndrome Colorectal Cancer Patients.

2021

ABSTRACT Background and aims Due to the high load of immunogenic frameshift neoantigens, tumors arising in individuals with Lynch syndrome (LS), the most common inherited colorectal cancer (CRC) syndrome, are characterized by a pronounced immune infiltration. However, the immune status of normal colorectal mucosa in LS is not well characterized. We assessed the immune infiltrate in tumor-distant normal colorectal mucosa from LS CRC patients, sporadic microsatellite-unstable (MSI) and microsatellite-stable (MSS) CRC patients, and cancer-free LS carriers. Methods CD3-positive, FOXP3-positive and CD8-positive T cells were quantified in 219, 233 and 201 formalin-fixed paraffin-embedded (FFPE) n…

MaleCD3 ComplexColorectal cancerT-LymphocytesCD8-Positive T-LymphocytesT-Lymphocytes Regulatory0302 clinical medicineIntestinal MucosaMismatch Repair Endonuclease PMS2Aged 80 and over0303 health sciencesbiologyGastroenterologyFOXP3Forkhead Transcription FactorsMiddle AgedLynch syndrome3. Good healthDNA-Binding Proteinsmedicine.anatomical_structureMutS Homolog 2 Protein030220 oncology & carcinogenesisFemaleMicrosatellite InstabilityMutL Protein Homolog 1AdultHeterozygoteColonT cellCD303 medical and health sciencesYoung AdultImmune systemmedicineHumansLymphocyte Count030304 developmental biologyAgedHepatologybusiness.industryCarcinomaRectumCancerMicrosatellite instabilitymedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisCancer researchbiology.proteinbusinessTranscriptomeGastroenterology
researchProduct

Somatic mutation profiles as molecular classifiers of ulcerative colitis-associated colorectal cancer.

2021

Ulcerative colitis increases colorectal cancer risk by mechanisms that remain incompletely understood. We approached this question by determining the genetic and epigenetic profiles of colitis-associated colorectal carcinomas (CA-CRC). The findings were compared to Lynch syndrome (LS), a different form of cancer predisposition that shares the importance of immunological factors in tumorigenesis. CA-CRCs (n=27) were investigated for microsatellite instability, CpG island methylator phenotype, and somatic mutations of 999 cancer-relevant genes ("Pan-cancer" panel). A subpanel of "Pan-cancer" design (578 genes) was used for LS colorectal tumors (n=28). Mutational loads and signatures stratifie…

MaleCancer ResearchColorectal cancermedicine.disease_cause0302 clinical medicinesomatic mutationPromoter Regions Genetictulehdukselliset suolistosairaudetMiddle AgedLynch syndrome3. Good healthOncology030220 oncology & carcinogenesissyöpätauditDNA mismatch repairFemaleMicrosatellite InstabilityMutL Protein Homolog 1Adult3122 Cancerscolorectal cancersuolistosyövätBiologymikrosatelliititMLH103 medical and health sciencesGermline mutationmedicineHumansLynchin oireyhtymäulcerative colitisDNA-analyysiCpG Island Methylator PhenotypeMicrosatellite instabilitySequence Analysis DNADNA Methylationmedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisLynch syndromeUlcerative colitisMutationCancer researchmicrosatellite instabilityColitis UlcerativeCpG IslandsmutaatiotColitis-Associated NeoplasmsTumor Suppressor Protein p53CarcinogenesisInternational journal of cancerREFERENCES
researchProduct

Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine

2009

Background: Despite having a dramatically larger surface area than the large intestine, the small intestine is an infrequent site for the development of adenocarcinoma. To better understand the molecular abnormalities in small bowel adenocarcinoma (SBA), we characterised a number of candidate oncogenic pathways and the immunophenotype of this rare cancer. Methods: Tissue microarrays were constructed from tumour samples from 54 patients with all stages of the disease. Immunohistochemistry and microsatellite instability (MSI) testing were conducted. Results: The profile of cytokeratin 20 and 7 coexpression was variable, but expression of caudal type homeobox transcription factor 2 (CDX2) was …

MaleCancer ResearchPathologyReceptor ErbB-2Kaplan-Meier EstimateDNA Mismatch Repairchemistry.chemical_compoundDuodenal NeoplasmsCDX2 Transcription Factorsmall bowel adenocarcinomaCDX2Letter to the EditorOligonucleotide Array Sequence Analysisvascular endothelial growth factorbiologyMiddle AgedNeoplasm ProteinsErbB ReceptorsVascular endothelial growth factormismatch repairOncologyimmunohistochemistryKeratinsAdenocarcinomaFemaleMicrosatellite InstabilityAdultmedicine.medical_specialtyAdenocarcinomaImmunophenotypingCytokeratinGrowth factor receptormedicineHumansPTENAgedHomeodomain ProteinsJejunal NeoplasmsGene Expression ProfilingPTEN PhosphohydrolaseMicrosatellite instabilityCancerGenes erbB-1OncogenesGenes erbB-2medicine.diseasedigestive system diseasesIleal NeoplasmsReceptors Vascular Endothelial Growth Factorchemistrybiology.proteinTranslational Therapeuticsepidermal growth factor receptorBritish Journal of Cancer
researchProduct

Aberrant methylation within RUNX3 CpG island associated with the nuclear and mitochondrial microsatellite instability in sporadic gastric cancers. Re…

2007

Background: Gastric cancer (GC) development is a multistep process, during which numerous alterations accumulate in nuclear and mitochondrial DNA. A deficiency of repair machinery brings about an accumulation of errors introduced within simple repetitive microsatellite sequences during replication of DNA. Aberrant methylation is related to microsatellite instability (MSI) by the silencing of the hMLH1 gene. The aim of this study is to investigate a possible relationship between the RUNX3 promoter methylation, nuclear microsatellite instability (nMSI) and mitochondrial microsatellite instability (mtMSI), in order to clarify its biological role in GC. Patients and methods: nMSI and mtMSI were…

MaleMitochondrial DNAGC Rich SequenceBiologyDNA Mitochondriallaw.inventionlawStomach NeoplasmsmedicineHumansGenetic Predisposition to DiseaseProspective StudiesPolymerase chain reactionAgedCell NucleusCancerMicrosatellite instabilityHematologyMethylationDNA MethylationMiddle Agedmedicine.diseaseMolecular biologydigestive system diseasesCore Binding Factor Alpha 3 SubunitOncologyCpG siteMicrosatelliteCpG IslandsFemaleMicrosatellite InstabilityMicrosatellite Repeats
researchProduct

Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chem…

2014

Background & Aims Patients with colorectal tumors with microsatellite instability (MSI) have better prognoses than patients with tumors without MSI, but have a poor response to 5-fluorouracil–based chemotherapy. A dominant-negative form of heat shock protein (HSP)110 (HSP110DE9) expressed by cancer cells with MSI, via exon skipping caused by somatic deletions in the T 17 intron repeat, sensitizes the cells to 5-fluorouracil and oxaliplatin. We investigated whether HSP110 T 17 could be used to identify patients with colorectal cancer who would benefit from adjuvant chemotherapy with 5-fluorouracil and oxaliplatin. Methods We characterized the interaction between HSP110 and HSP110DE9 using su…

MaleModels MolecularOrganoplatinum CompoundsColorectal cancermedicine.medical_treatment[SDV]Life Sciences [q-bio]Leucovorin0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsHSP110 Heat-Shock ProteinsComputingMilieux_MISCELLANEOUSColectomySequence Deletion0303 health sciencesGastroenterologyPrimary tumor3. Good healthOxaliplatinTreatment OutcomeFluorouracilChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleMicrosatellite InstabilityFluorouracilColorectal Neoplasmsmedicine.drugBlotting WesternAntineoplastic AgentsBiology03 medical and health sciencesCell Line TumormedicineBiomarkers TumorHumans030304 developmental biologyAgedRetrospective StudiesChemotherapyHepatologyBase SequenceMicrosatellite instabilityCancerSurface Plasmon Resonancemedicine.diseaseMolecular biologySurvival AnalysisIntronsOxaliplatinCancer cellCancer researchFollow-Up StudiesGastroenterology
researchProduct

The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, …

2005

Purpose The aims of the TP53 Colorectal Cancer (CRC) International Collaborative Study were to evaluate the possible associations between specific TP53 mutations and tumor site, and to evaluate the prognostic and predictive significance of these mutations in different site, stage, and treatment subgroups. Patients and Methods A total of 3,583 CRC patients from 25 different research groups in 17 countries were recruited to the study. Patients were divided into three groups according to site of the primary tumor. TP53 mutational analyses spanned exons 4 to 8. Results TP53 mutations were found in 34% of the proximal colon tumors and in 45% of the distal colon and rectal tumors. They were assoc…

MaleOncologyCancer Researchmedicine.medical_specialtyPathologyRECTAL-CARCINOMATumor suppressor geneColorectal cancerLymphovascular invasionMICROSATELLITE INSTABILITYCELL LUNG-CANCERDNA Mutational AnalysisALLELIC LOSSDUKES STAGE-BMOLECULAR MARKERSInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineGenetic Predisposition to DiseaseNeoplasm InvasivenessStage (cooking)neoplasmsSurvival rateAgedNeoplasm Stagingbusiness.industryCOLON-CANCERMicrosatellite instabilityZINC-BINDING DOMAINExonsMiddle AgedWILD-TYPE P53medicine.diseaseAdenocarcinoma MucinousPrimary tumorSurvival RateOncologyChemotherapy AdjuvantMutationAdenocarcinomaFemaleZINC-BINDING DOMAIN; CELL LUNG-CANCER; DUKES STAGE-B; WILD-TYPE P53; GENETIC PATHWAYS; COLON-CANCER; MICROSATELLITE INSTABILITY; MOLECULAR MARKERS; RECTAL-CARCINOMA; ALLELIC LOSSGENETIC PATHWAYSTumor Suppressor Protein p53Colorectal NeoplasmsbusinessFollow-Up Studies
researchProduct

Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel Adenocarcinomas

2020

Abstract Background Small bowel adenocarcinoma is a relatively rare cancer, often diagnosed in an advanced stage. In localized and resectable disease, surgery alone or in combination with adjuvant chemotherapy is the mainstay of treatment. In the recently published National Comprehensive Cancer Network Clinical Practice guidelines, criteria for selecting patients with stage II small bowel adenocarcinoma to receive adjuvant chemotherapy are provided, and they are mainly extrapolated from studies on colorectal cancer. Patients and Methods In the present study, we aimed to verify whether mismatch repair deficiency phenotype, high-risk pathologic features (including T4, positive resection margi…

MaleOncologyColorectal cancerDNA Mismatch RepairCOLORECTAL-CANCERSettore MED/120302 clinical medicinePMS2small bowel adenocarcinomaMismatch Repair Endonuclease PMS20303 health sciencesPrognosisMMRMutS Homolog 2 ProteinOncologyCARCINOMAS030220 oncology & carcinogenesisimmunohistochemistryMismatch Repair Status small bowel adenocarcinomaFemaleMicrosatellite InstabilityDNA mismatch repairMutL Protein Homolog 1Colorectal Neoplasmsstage IImedicine.medical_specialtyhigh-risk pathologic featuresDNA Mismatch Repair; Female; Humans; Male; Microsatellite Instability; Mismatch Repair Endonuclease PMS2; MutL Protein Homolog 1; MutS Homolog 2 Protein; Prognosis; Adenocarcinoma; Colorectal Neoplasmssmall bowel adenocarcinoma; mismatch repair statusAdenocarcinomaNO03 medical and health sciencessmall bowel carcinomahistotypeInternal medicineTranslational ResearchmedicineHumansmismatch repair status030304 developmental biologysmall bowel adenocarcinomasbusiness.industryCancerMicrosatellite instabilityMismatch Repair ProteinAdenocarcinoma IBD Cancermedicine.diseasedigestive system diseasesMSH6COLORECTAL-CANCER; CARCINOMAS; CONSENSUSsmall bowel carcinoma MMR immunohistochemistryMismatch repair Small bowel AdenocarcinomaMSH2Mismatch repair status; stage II; small bowel adenocarcinomas; histotype; high-risk pathologic featuresSurgeryCONSENSUSbusiness
researchProduct

Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice.

2010

BACKGROUND & AIMS: The limited clinical response observed in many patients with colorectal cancer may be related to the presence of chemoresistant colorectal can- cer stem cells (CRC-SCs). Bone morphogenetic protein 4 (BMP4) promotes the differentiation of normal colonic stem cells. We investigated whether BMP4 might be used to induce differentiation of CRC-SCs and for therapeutic purposes. METHODS: CRC-SCs were isolated from 25 tumor samples based on expression of CD133 or using a selection culture medium. BMP4 expression and activity on CRC-SCs were evaluated in vitro; progeny of the stem cells were evaluated by immunofluorescence, immuno- blot, and flow cytometry analyses. The potential …

MaleOrganoplatinum CompoundsCellular differentiationDrug ResistanceApoptosisBone Morphogenetic Protein 4Colon Cancer; Drug Resistance; Neoplasia; Tumor Resistance to Chemotherapy; AC133 Antigen; Adenomatous Polyposis Coli; Aged; Aged 80 and over; Animals; Antigens CD; Antineoplastic Agents; Apoptosis; Bone Morphogenetic Protein 4; Cell Differentiation; Cells Cultured; Colorectal Neoplasms; Female; Fluorouracil; Glycoproteins; Humans; Male; Mice; Microsatellite Instability; Middle Aged; Mutation; Neoplastic Stem Cells; Organoplatinum Compounds; PTEN Phosphohydrolase; Peptides; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Smad4 Protein; GastroenterologyMice80 and overBone morphogenetic protein receptorAC133 AntigenCells CulturedSmad4 ProteinAged 80 and overCulturedColon Cancerintegumentary systemGastroenterologyCell DifferentiationBMP4 colon stem cellsMiddle AgedCDOxaliplatinTumor Resistance to ChemotherapyBone morphogenetic protein 4Adenomatous Polyposis Coliembryonic structuresNeoplastic Stem CellsFemaleMicrosatellite InstabilityFluorouracilStem cellColorectal Neoplasmsanimal structuresCellsAntineoplastic AgentsBiologyBone morphogenetic proteinSettore MED/04 - PATOLOGIA GENERALECancer stem cellAntigens CDPTENAnimalsHumansAntigensneoplasmsPI3K/AKT/mTOR pathwayAgedGlycoproteinsNeoplasiaHepatologyPTEN Phosphohydrolasedigestive system diseasesMutationCancer researchbiology.proteinPhosphatidylinositol 3-KinasePeptidesProto-Oncogene Proteins c-aktGastroenterology
researchProduct